Serum Levels of Lipopolysaccharide and 1,3- β -D-Glucan Refer to the Severity in Patients with Crohn's Disease

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Guo, Yanmin ^a   Zhou, Guangxi ^a   He, Chong ^a   Yang, Wenjing ^a   He, Zhenkun ^b   Liu, Zhanju ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b HENAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; ENDOTOXIN; INFLIXIMAB; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR; BETA GLUCAN; BETA-1,3-GLUCAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DOWN REGULATION; FEMALE; HUMAN; INTESTINE MUCOSA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; BLOOD; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

BACTERIA (MICROORGANISMS);

ADOLESCENT; ADULT; BETA-GLUCANS; CHILD; CROHN DISEASE; FEMALE; HUMANS; INFLIXIMAB; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84935834924     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/843089     Document Type: Article

References (47)

1. D. C. Baumgart and W. J. Sandborn, "Crohns disease," The Lancet, vol. 380, no. 9853, pp. 1590-1605, 2012.
2. A. Aujnarain, D. R. Mack, and E. I. Benchimol, "The role of the environment in the development of pediatric inflammatory bowel disease," Current Gastroenterology Reports, vol. 15, no. 6, article 326, 2013.
3. C. Fiocchi, "Inflammatory bowel disease: evolutionary concepts in biology, epidemiology, mechanisms and therapy," Current Opinion in Gastroenterology, vol. 29, no. 4, pp. 347-349, 2013.
4. H. F. Hammer, "Gut microbiota and inflammatory bowel disease," Digestive Diseases, vol. 29, no. 6, pp. 550-553, 2011.
5. X.-R. Xu, C.-Q. Liu, B.-S. Feng, and Z.-J. Liu, "Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease," World Journal of Gastroenterology, vol. 20, no. 12, pp. 3255-3264, 2014.
6. M. Dave, P. D. Higgins, S. Middha, and K. P. Rioux, "The human gut microbiome: current knowledge, challenges, and future directions," Translational Research, vol. 160, no. 4, pp. 246-257, 2012.
7. A. D. Kostic, R. J. Xavier, and D. Gevers, "The microbiome in inflammatory bowel disease: current status and the future ahead," Gastroenterology, vol. 146, no. 6, pp. 1489-1499, 2014.
8. F. Scaldaferri, M. Pizzoferrato, V. Gerardi, L. Lopetuso, and A. Gasbarrini, "The gut barrier: new acquisitions and therapeutic approaches," Journal of Clinical Gastroenterology, vol. 46, no. 1, Supplement, pp. S12-S17, 2012.
9. M. Martinez-Medina, X. Aldeguer, M. Lopez-Siles et al., "Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohns disease," Inflammatory Bowel Diseases, vol. 15, no. 6, pp. 872-882, 2009.
10. A.-L. Glasser, J. Boudeau, N. Barnich, M.-H. Perruchot, J.-F. Colombel, and A. Darfeuille-Michaud, "Adherent invasive Escherichia coli strains from patients with Crohns disease survive and replicate within macrophages without inducing host cell death," Infection and Immunity, vol. 69, no. 9, pp. 5529-5537, 2001.
11. S. Meconi, A. Vercellone, F. Levillain et al., "Adherent-invasive Escherichia coli isolated from Crohns disease patients induce granulomas in vitro," Cellular Microbiology, vol. 9, no. 5, pp. 1252-1261, 2007.
12. S. J. Ott, M. Musfeldt, D. F. Wenderoth et al., "Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease," Gut, vol. 53, no. 5, pp. 685-693, 2004.
13. R. Bringiotti, E. Ierardi, R. Lovero, G. Losurdo, A. D. Leo, and M. Principi, "Intestinal microbiota: the explosive mixture at the origin of inflammatory bowel disease?" World Journal of Gastrointestinal Pathophysiology, vol. 5, no. 4, pp. 550-559, 2014.
14. J. L. Benjamin, C. R. H. Hedin, A. Koutsoumpas et al., "Smokers with active Crohns disease have a clinically relevant dysbiosis of the gastrointestinal microbiota," Inflammatory Bowel Diseases, vol. 18, no. 6, pp. 1092-1100, 2012.
15. X. C. Morgan, T. L. Tickle, H. Sokol et al., "Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment," Genome Biology, vol. 13, no. 9, p. R79, 2012.
16. A. K. Samanta, V. A. Torok, N. J. Percy, S. M. Abimosleh, and G. S. Howarth, "Microbial fingerprinting detects unique bacterial communities in the faecal microbiota of rats with experimentally-induced colitis," Journal ofMicrobiology, vol. 50, no. 2, pp. 218-225, 2012.
17. H. Qiu, X. Sun, M. Sun, C. He, Z. Li, and Z. Liu, "Serumbacterial toxins are related to the progression of inflammatory bowel disease," Scandinavian Journal of Gastroenterology, vol. 49, no. 7, pp. 826-833, 2014.
18. S. Nikolaus and S. Schreiber, "Diagnostics of inflammatory bowel disease," Gastroenterology, vol. 133, no. 5, pp. 1670-1689, 2007.
19. M. Daperno, G. DHaens, G. van Assche et al., "Development and validation of a new, simplified endoscopic activity score for Crohns disease: the SES-CD," Gastrointestinal Endoscopy, vol. 60, no. 4, pp. 505-512, 2004.
20. E. S. Yuksel, S. Ipek, F. Topal et al., "Assessment of presence and grade of activity in ileal Crohn's disease," The Turkish Journal of Gastroenterology, vol. 25, no. 3, pp. 264-270, 2014.
21. J. Satsangi, M. S. Silverberg, S. Vermeire, and J.-F. Colombel, "The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications," Gut, vol. 55, no. 6, pp. 749-753, 2006.
22. C. Liu, X. Xia, W. Wu et al., "Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohns disease," Clinical and Experimental Immunology, vol. 173, no. 1, pp. 102-111, 2013.
23. J. Marchesi and F. Shanahan, "The normal intestinal microbiota," Current Opinion in Infectious Diseases, vol. 20, no. 5, pp. 508-513, 2007.
24. R. Tojo, A. Suarez, M. G. Clemente et al., "Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis," World Journal of Gastroenterology, vol. 20, no. 41, pp. 15163-15176, 2014.
25. M. G. Dominguez-Bello, M. J. Blaser, R. E. Ley, and R. Knight, "Development of the human gastrointestinal microbiota and insights from high-throughput sequencing," Gastroenterology, vol. 140, no. 6, pp. 1713-1719, 2011.
26. B. Khor, A. Gardet, and R. J. Xavier, "Genetics and pathogenesis of inflammatory bowel disease," Nature, vol. 474, no. 7351, pp. 307-317, 2011.
27. Z. Liu, A. T. Cao, and Y. Cong, "Microbiota regulation of inflammatory bowel disease and colorectal cancer," Seminars in Cancer Biology, vol. 23, no. 6, pp. 543-552, 2013.
28. J. Bien, V. Palagani, and P. Bozko, "The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?" Therapeutic Advances in Gastroenterology, vol. 6, no. 1, pp. 53-68, 2013.
29. P. Lepage, J. Colombet, P. Marteau, T. Sime-Ngando, J. Dore, and M. Leclerc, "Dysbiosis in inflammatory bowel disease: a role for bacteriophages?" Gut, vol. 57, no. 3, pp. 424-425, 2008.
30. D. R. Dixon and R. P. Darveau, "Lipopolysaccharide heterogeneity: innate host responses to bacterial modification of lipid A structure," Journal of Dental Research, vol. 84, no. 7, pp. 584-595, 2005.
31. H. Mohanram and S. Bhattacharjya, " β-boomerang antimicrobial and antiendotoxic peptides: lipidation and disulfide bond effects on activity and structure," Pharmaceuticals, vol. 7, no. 4, pp. 482-501, 2014.
32. M. E. V. Johansson, J. K. Gustafsson, K. E. Sjoberg et al., "Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model," PLoS ONE, vol. 5, no. 8, Article ID e12238, 2010.
33. S. de Kivit, M. C. Tobin, C. B. Forsyth, A. Keshavarzian, and A. L. Landay, "Regulation of intestinal immune responses through TLR activation: implications for pro-and prebiotics," Frontiers in Immunology, vol. 5, article 60, 2014.
34. R. F. Leal, M. Milanski, M. D. L. S. Ayrizono et al., "Toll-like receptor 4, F4/80 and pro-infammatory cytokines in intestinal and mesenteric fat tissue of Crohns disease," International Journal of Clinical and Experimental Medicine, vol. 6, no. 2, pp. 98-104, 2013.
35. B. Chassaing, O. Koren, F. A. Carvalho, R. E. Ley, and A. T. Gewirtz, "AIEC pathobiont instigates chronic colitis in susceptible hosts by alteringmicrobiota composition," Gut, vol. 63, no. 7, pp. 1069-1080, 2013.
36. M. M. Heimesaat, S. Bereswill, A. Fischer et al., "Gramnegative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii," The Journal of Immunology, vol. 177, no. 12, pp. 8785-8795, 2006.
37. C. R. Weber and J. R. Turner, "Inflammatory bowel disease: is it really just another break in the wall?" Gut, vol. 56, no. 1, pp. 6-8, 2007.
38. F. Scaldaferri, L. R. Lopetuso, V. Petito et al., "Gelatin tannate ameliorates acute colitis in mice by reinforcingmucus layer and modulating gut microbiota composition: emerging role for gut barrier protectors in IBD?" United European Gastroenterology Journal, vol. 2, no. 2, pp. 113-122, 2014.
39. M. M. Heimesaat, A. Fischer, H.-K. Jahn et al., "Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli," Gut, vol. 56, no. 7, pp. 941-948, 2007.
40. M. Chiba, K. Mikami, M. Iizuka et al., "Elevated plasma (1 → 3)-β-D-glucan, a fungal cell wall constituent, in a subgroup of Crohn disease," Scandinavian Journal of Gastroenterology, vol. 36, no. 4, pp. 447-448, 2001.
41. S. Suram, G. D. Brown, M. Ghosh et al., "Regulation of cytosolic phospholipase A2 activation and cyclooxygenase 2 expression in macrophages by the β-glucan receptor," The Journal of Biological Chemistry, vol. 281, no. 9, pp. 5506-5514, 2006.
42. S. Vermeire, G. Van Assche, and P. Rutgeerts, "Laboratory markers in IBD: useful, magic, or unnecessary toys?" Gut, vol. 55, no. 3, pp. 426-431, 2006.
43. A. M. Schoepfer, C. Beglinger, A. Straumann et al., "Fecal calprotectin correlates more closely with the simple endoscopic score for crohns disease (SES-CD) than CRP, blood leukocytes, and the CDAI," The American Journal of Gastroenterology, vol. 105, no. 1, pp. 162-169, 2010.
44. T. Sipponen, H. Nuutinen, U. Turunen, and M. Farkkila, "Endoscopic evaluation of Crohns disease activity: comparison of the CDEIS and the SES-CD," Inflammatory Bowel Diseases, vol. 16, no. 12, pp. 2131-2136, 2010.
45. A. Yesil, E. Senates, I. V. Bayoglu, E. D. Erdem, R. Demirtunc, and A. O. K. Ovunc, "Red cell distributionwidth: a novelmarker of activity in inflammatory bowel disease," Gut and Liver, vol. 5, no. 4, pp. 460-467, 2011.
46. H. Wajant, K. Pfizenmaier, and P. Scheurich, "Tumor necrosis factor signaling," Cell Death and Differentiation, vol. 10, no. 1, pp. 45-65, 2003.
47. S. B. Hanauer, "The expanding role of biologic therapy for IBD," Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 2, pp. 63-64, 2010.